menu
    • menu
    [{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"Factor VII","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"Factor VIIa","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CT-001","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for CT-001

    Menu

    CT-001

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Announces Publication in Blood Advances Describing Novel Nanobody Library to Activated ...

                            Details : CT-001 is an engineered FVIIa that is designed to address the limitations of the recombinant FVIIa, approved for use in Hemophilia A and B patients with inhibitors, congenital FVII deficiency and Glanzmann’s thrombasthenia with refractoriness to platel...

                            Brand Name : CT-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 27, 2023

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Announces Upcoming Oral and Poster Presentations at the 2022 American Society of Hemato...

                            Details : CT-001 is an engineered version of FVIIa that is designed to address the limitations of the recombinant FVIIa, approved for use in Hemophilia A and B patients with inhibitors, congenital FVII deficiency.

                            Brand Name : CT-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 16, 2022

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Presents Data for Severe Postpartum Hemorrhage Clinical Candidate, CT-001, at Internati...

                            Details : CT-001 is an engineered version of clotting factor FVIIa designed to address safety and efficacy limitations of recombinant FVIIa is approved for use in Hemophilia A and B patients with inhibitors.

                            Brand Name : CT-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : CT-001

                            Therapeutic Area : Hematology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Coagulant Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Coagulant Therapeutics Announces Publication of In Vivo Data Demonstrating Safety and Efficacy of CT-001 for t...

                            Details : The in vivo studies compared the safety and efficacy of CT-001 versus recombinant FVIIa in multiple mouse models. The studies confirmed that desialylation of the molecule increased the speed by which it cleared from the body.

                            Brand Name : CT-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 07, 2022

                            Lead Product(s) : CT-001

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth